Introduction
The WHO Collaborating Centre for Reference and Research on Influenza in Melbourne is part of the World Health Organization Global Influenza Surveillance and Response System (WHO GISRS). The GISRS is a worldwide network of laboratories that was established in 1952 to monitor changes in influenza viruses circulating in the human population with the aim of reducing its impact through the use of vaccines and antiviral medications. The Centre in Melbourne is one of 5 such Collaborating Centres (the others being in Atlanta, Beijing, London and Tokyo) that monitor the antigenic and genetic changes in circulating human influenza viruses, and makes bi-annual recommendations on which influenza strains should be included in the influenza vaccine for the upcoming winter season in either the northern or southern hemisphere. This report summarises the results of virological surveillance activities undertaken at the Centre in Melbourne during 2016.
Two types of influenza cause significant disease in humans: types A and B. Influenza A viruses are further classified into subtypes, based on their haemagglutinin (HA) and neuraminidase (NA) surface proteins. Globally, there are currently 2 influenza A subtypes circulating in human populations A(H1N1)pdm09 and A(H3N2). Influenza B viruses are not classified into subtypes; however, there are 2 distinct co-circulating lineages of influenza B viruses -B/Victoria/2/87 (B/Victoria lineage) and B/ Yamagata/16/88 (B/Yamagata lineage). In addition, each year influenza C viruses are detected from humans, but these viruses tend not to cause severe disease and are not a major focus of surveillance.
Methods

Virus isolation
All A(H1)pdm09 and all influenza B viral isolates received at the Centre were re-passaged in cell culture (Madin-Darby Canine Kidney (MDCK) cells), whilst all A(H3) viral isolates were re-passaged in MDCK-SIAT1 cells.
1 Virus isolation was also attempted from a selection of original clinical specimens received. In addition, influenza positive original clinical samples were directly inoculated into eggs as potential candidate vaccine viruses (CVVs).
Antigenic analysis
The antigenic properties of influenza viral isolates were analysed using the haemagglutination inhibition (HI) assay as previously described. 2 The majority of the HI assays were performed using the TECAN Freedom EVO200 robot platform which incorporates a camera (Sci Robotics) and imaging software (FluHema) for automated analysis. In HI assays, viruses were tested for their ability to agglutinate red blood cells in the presence of ferret antisera previously raised against reference viruses. Isolates were identified as antigenically similar to the reference strain if the test samples had a titre that was no more than 4-fold different from the titre of the homologous reference strain. 
Genetic analysis
For samples that failed to grow in MDCK cells, real-time RT-PCR was performed to determine the influenza type/subtype/lineage. The CDC For sequencing, RNA was extracted from isolates or original clinical specimens using either manual QIAGEN QIAamp spin columns method or the automated QIAGEN QIAXtractor robot, followed by reverse transcription PCR using the BIOLINE MyTaq one step reverse transcription PCR kit according to the manufacturer's recommendations with gene specific primers (primer sequences available on request). Conventional Sanger sequencing was carried out on PCR products using an Applied Biosystems 3500 XL sequencer. Sequence assembly was performed using the Seqman Pro Module of DNASTAR Lasergene version 13 software (DNASTAR, Madison, WI, USA). Next generation sequencing (NGS) was performed on a selection of viruses using an Applied Biosystems Ion Torrent Personal Genome Machine (PGM) System according to the manufacturer's recommendations. These sequences were analysed using a proprietary pipeline, FluLINE. Phylogenetic analysis was performed using Geneious 9.0.4 software (Biomatters Ltd, Auckland, New Zealand) and FigTree v1.3.1.
Antiviral drug resistance testing
As there is potential for influenza viruses to develop resistance to antiviral drugs, circulat-ing viruses were tested for their sensitivity to the currently used neuraminidase inhibitors oseltamivir (Tamiflu) and zanamivir (Relenza). The neuraminidase inhibition (NAI) assay used was a functional fluorescence-based assay using the substrate 20-(4-methylumbelliferyl)-a-D-Nacetylneuraminic acid (MUNANA) in which the susceptibility of test viruses to the antiviral drugs was measured in terms of the drug concentration needed to reduce the neuraminidase enzymatic activity by 50% (IC 50 ), and compared to values obtained with sensitive reference viruses of the same subtype or lineage. NAI assays were performed as previously described 4 with the incorporation of a robotic platform by TECAN EVO200 and Infinite 200Pro for liquid handling and plate reading (Tecan Australia). For the purposes of reporting, reduced inhibition of influenza A viruses was defined as a 10-99 fold increase in IC 50 , while highly reduced inhibition was defined as a ≥ 100-fold increase in IC 50 in a neuraminidase inhibition assay. For influenza B viruses, these figures were 5-49 fold and ≥50 fold increases, respectively. However, it should be noted that the relationship between the IC 50 value and the clinical effectiveness of a neuraminidase inhibitor is not well understood and a reduction in inhibition may not be clinically significant.
Viruses found to have highly reduced inhibition by either oseltamivir or zanamivir underwent further analysis to determine the presence of amino acid substitutions in the neuraminidase protein that were associated with the reduction of inhibition by NAIs. For example, a change from histidine to tyrosine at position 275 (H275Y) of the neuraminidase protein of A(H1N1)pdm09 viruses is known to reduce inhibition by oseltamivir, as does the H273Y neuraminidase mutation in B viruses. 
Candidate vaccine strains
The viruses used to produce human vaccines are required to be isolated and passaged in embryonated hen's eggs or qualified cell lines. The Centre undertook primary isolation of selected viruses from clinical samples directly into eggs, using previously described methods 6 , except for the following modifications. First, the viruses were initially inoculated into the amniotic cavity only, and once growth was established the isolates were then further passaged in the allantoic cavity. This was followed by harvest only from either the amniotic or allantoic cavity, depending on site of inoculation. Egg incubation conditions also differed slightly with A(H1) pdm09 and A(H3) viruses incubated at 35 o C for 3 days, and influenza B viruses incubated at 33 o C for 3 days. In addition, selected clinical samples were also inoculated into the qualified cell line MDCK 33016PF and incubated at 35 o C for 3 days and viral growth was monitored by haemagglutination of turkey or guinea pig red blood cells. These isolates were then analysed by HI assay, real time RT-PCR and genetic sequencing.
Results
During 2016, the Centre received 4,247 clinical specimens and/or virus isolates from 35 laboratories in 14 countries ( Figure 1 ). As in previous years, most samples were submitted by laboratories in the Asia-Pacific region, including Australian laboratories 7 and were received during the Southern Hemisphere influenza season. Figure 2 shows the temporal distribution of samples sent to the Centre by type/subtype and lineage.
Isolation was attempted for 4,014 (95%) of the samples received, which yielded 3,250 isolates (81% isolation rate). In total, 998 A(H1)pdm09, 1594 A(H3) and 653 B viruses (90%, 92% and 97% respectively of viruses for which isolation was attempted) were obtained. However, 480 A(H3) isolates did not reach sufficient titres for antigenic analysis due to their low HA in the presence of oseltamivir carboxylate. A total of 2,473 viral isolates were successfully characterised by HI assay in comparison to the 2016 vaccine-like viruses (Table 1 ). In addition, 250 samples were characterised by real-time RT-PCR to determine their type/subtype or lineage. Sanger sequencing and NGS techniques were used to sequence the haemagglutinin genes of 955 viruses. The full genomes of 102 viruses 
A(H1N1)pdm09
Of the 990 A(H1)pdm09 isolates analysed by HI assay using ferret antisera in 2016, the majority (95%) were antigenically similar to the vaccine reference strain A/California/7/2009 (Table 1) .
Sequencing and phylogenetic analysis of HA genes from 250 viruses showed that A(H1)pdm09 viruses sent to the Centre during 2016 fell mainly into the 6B.1 subclade with a smaller number of viruses in subclade 6B.2 ( Figure 3) . No antigenic differences were detectable between viruses from the 6B, 6B.1 or 6B.2 genetic clades in ferret antisera HI assays and the majority of viruses reacted in a similar manner to the reference and 2016 vaccine virus A/California/7/2009. 49 viruses were inoculated into eggs for vaccine candidate strain isolation. Of these, 22 (45%) were successfully isolated, including viruses from each of the 2 emerging subclades (16 viruses from subclade 6B.1, five viruses from subclade 6B.2 and one virus from clade 6B).
Of 998 A(H1)pdm09 viruses tested, 6 exhibited highly reduced inhibition by oseltamivir. These viruses were from Singapore, Malaysia, Vietnam and Australia, and all contained the H275Y mutation in their NA genes. No A(H1)pdm09 viruses received during 2016 showed highly reduced inhibition to zanamivir. 
A(H3N2)
Antigenic analysis of 830 A(H3) subtype isolates using the HI assay showed that 15% were low reactors to the ferret antisera prepared against the cell-propagated reference strain A/Hong Kong/4801/2014 (Table 1) . However, 48% of viruses were low reactors to the ferret antisera prepared against the egg-propagated strain A/ Hong Kong/4801/2014 (data not shown). An additional 480 A(H3) viruses were inoculated and/or isolated by cell culture but did not reach sufficient titres for antigenic analysis, whilst a further 269 were successfully isolated but did not reach sufficient titres when tested by HI assay in the presence of oseltamivir carboxylate. 
Discussion
Similar to previous years, the samples received in 2016 were largely from Australia. 7, 8 During the Australian 2016 season there was lower influenza activity with fewer laboratoryconfirmed cases than in 2015, which had the highest activity since the pandemic in 2009. 9 Early interseasonal activity in 2016 was largely driven by A(H1)pdm09 viruses, followed by a rapid increase in the number of A(H3) viruses from July onwards. 10 This was also reflected in the samples received at the Centre during 2016, where viruses collected from late June onwards were predominated by A(H3). In years where A(H3) viruses predominate, the elderly are disproportionately affected 11 and this was reflected in the higher number of notification rates in adults aged ≥75 years. 10 HI assays performed at the Centre showed that at least 85% of A(H3) viruses tested were antigenically similar to the cell-propagated reference strain A/Hong Kong/4801/2014. However, approximately half of the viruses analysed at the Centre were low reactors to the egg derived A/ Hong Kong/4801/2014 reference strain (data not shown). In recent years there have been considerable challenges in the antigenic characterisation of A(H3) viruses. Evolutionary changes in this subtype have made it difficult to detect antigenic changes using the HI assay. 3, 12 A large number of A(H3) viruses isolated in MDCK-SIAT-1 cells cannot be assayed by HI in the presence of oseltamivir carboxylate and have to be antigenically tested using microneutralisation assays such as plaque reduction assays or focus reduction assays. Only 45% of all A(H3) viruses received by the Centre during 2016 could be analysed by the HI assay. The Centre is continuing to work on the development of other assays (e.g. virus neutralisation) to characterise the antigenicity of recent A(H3) viruses, however at this time, such assays remain time-and labourintensive and would most likely complement rather than replace the HI assay. Genetic analysis has therefore become an increasingly important tool for detecting both minor and major changes in circulating A(H3) viruses. Similar estimates have also been reported in Canada (VE 42%; 95% CI: 18 -59%) 14 and the US (VE 43%; 95% CI: 29 -54%). 15 . This was also reflected in good vaccine effectiveness estimates from the northern hemisphere (VE 73%, 95% CI: 54-84%). 15 The viral isolates of two B/Victoria viruses with highly reduced inhibition to both oseltamivir and zanamivir were each found to contain a single amino acid change in their respective NA sequences. However, the original clinical specimens of these isolates were not available for analysis. Therefore, it could not be determined whether these mutations were present in the original sample or whether they arose during virus propagation in cell culture.
With the continual change and evolution in influenza viruses and the absence of a universal vaccine, there remains a need for ongoing influenza surveillance and influenza vaccine updates. The work performed by the Centre in Melbourne is crucial to the efforts of the global surveillance community to ensure that viruses recommended for the influenza vaccine remain updated and as closely matched to the future circulating viruses as possible.
